12.22
0.02 (0.16%)
0.02 (0.16%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 8,352,907 |
|
|||||
| News | - | ||||||
| Day High | 12.29 | Low High |
|||||
| Day Low | 12.085 | ||||||
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Viatris Inc | VTRS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.02 | 0.16% | 12.22 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 12.23 | 12.085 | 12.29 | 12.195 | 12.20 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 45,599 | 8,352,907 | $ 12.19 | $ 101,818,570 | - | 11.96 - 18.86 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:48:43 | 50 | $ 12.23 | USD |
Period:
Draw Mode:
Viatris Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 14.78B | 1.21B | 1.08B | $ 11.95B | $ -1.35B | -1.11 | -5.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 3.61% | 11/22/21 | 12.44k | 0.30% |
Viatris News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VTRS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 12.85 | 12.90 | 11.96 | 12.37 | 14,069,031 | -0.63 | -4.9% |
| 1 Month | 13.75 | 14.87 | 11.96 | 13.38 | 12,231,578 | -1.53 | -11.13% |
| 3 Months | 14.37 | 14.87 | 11.96 | 13.49 | 9,043,579 | -2.15 | -14.96% |
| 6 Months | 15.44 | 15.92 | 11.96 | 13.97 | 7,788,063 | -3.22 | -20.85% |
| 1 Year | 17.1358 | 18.86 | 11.96 | 15.02 | 9,461,488 | -4.92 | -28.69% |
| 3 Years | 16.46 | 18.86 | 11.96 | 15.20 | 9,990,858 | -4.24 | -25.76% |
| 5 Years | 16.46 | 18.86 | 11.96 | 15.20 | 9,990,858 | -4.24 | -25.76% |
Viatris Description
| The new entity will largely be led by Pfizer executives and will be registered in Delaware. The new entity is anticipated to leverage the stand-alone Mylan infrastructure consisting of roughly 55 manufacturing and research and development facilities and that were largely acquired, including Matrix Laboratories and the generics business of Germany-based Merck KGaA. The combined portfolio will consist of the mature Upjohn drugs with notably better economics and Mylan's portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines, including EpiPen (treatment for anaphylaxis acquired through the Merck KGaA transaction). Unlike its generic peers, the company has made the most progress on the biosimilar front. |
